{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-098421","form_type":"8-K","ticker":"CERO","cik":"0001870404","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2025-10-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.929719+00:00","generated_at":"2026-05-17T03:58:54.843030+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CERo Therapeutics raises up to $7M via Series E convertible preferred private placement","bullets":["Initial closing of ~$1.8M; Series E convertible at $1,000 stated value, conversion price $4.1625 per share.","Series C and D conversion price reduced to $1.76 as consent for pari passu treatment with Series E.","Company to seek stockholder approval by Oct 31, 2025 for lower conversion; meeting target Dec 31, 2025.","Bankruptcy trigger and company optional redemption each at 25% premium.","Registration rights agreement filed to register resale of conversion shares."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-098421","json":"https://secwatch.observer/filing/0001213900-25-098421.json","markdown":"https://secwatch.observer/filing/0001213900-25-098421.md","text":"https://secwatch.observer/filing/0001213900-25-098421.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1870404/000121390025098421/0001213900-25-098421-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1870404/000121390025098421/ea0260318-8k_cero.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T03:58:54.843030+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1ad1bd55ee77d256ad36a2ca50e71861f4a4fa91","claim":"CERO THERAPEUTICS HOLDINGS, INC. issued up to 9,750 shares of the Company's Series E convertible preferred stock of preferred stock to certain accredited investors named therein (the \"PIPE Investors\") for aggregate purchase price of up to $7 million.","evidence_excerpt":"Pursuant to the Securities Purchase Agreement, up to 9,750 shares of the Company’s Series E convertible preferred stock, par value $0.0001 per share (the “ Series E Preferred Stock ”) shall be purchased for an aggregate purchase price of up to $7 million in one or more closings","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390025098421/0001213900-25-098421-index.htm","confidence":0.9,"family_label":"Equity Issuances","details":[{"label":"Security","value":"preferred stock"},{"label":"Shares","value":"up to 9,750 shares of the Company's Series E convertible preferred stock"},{"label":"Purchaser","value":"certain accredited investors named therein (the \"PIPE Investors\")"},{"label":"Consideration","value":"aggregate purchase price of up to $7 million"}],"fact_type":"equity_issuance"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}